{"title":"持续肾脏替代疗法：应用肾脏疾病改善急性肾损伤犬治疗处方的全球结局指南和结局预测","authors":"Hilli Raskansky, Yaron Bruchim, Ran Nivy","doi":"10.1111/jvim.70183","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Continuous renal replacement therapy (CRRT) is routinely used in human patients with acute kidney injury (AKI) but studies in dogs are scarce.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To describe CRRT in dogs and assess the utility of a previously validated scoring system for dogs with AKI undergoing hemodialysis, and the Acute Patient Physiological and Laboratory Evaluation (APPLE<sub>Full</sub>/APPLE<sub>Fast</sub>) scores, for outcome prediction.</p>\n </section>\n \n <section>\n \n <h3> Animals</h3>\n \n <p>Thirty, client-owned dogs.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Cases were retrospectively reviewed. Prognostic scores were calculated upon admission and before CRRT initiation. The CRRT effluent dose followed the KDIGO guidelines. Receiver operating characteristic curves (ROCC) were constructed to evaluate the prognostic utility of these scores.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Median (IQR) serum creatinine (mg/dL) at CRRT initiation, at discharge, and 3 months after discharge were 9.4 (7.4), 3.4 (1), and 1.3 (0.3) respectively. Median (IQR) treatment duration and total number of treatments were 24 (18.5) h and 2 (2) treatments, respectively. The prescribed median (IQR) CRRT effluent dose was 29 (18.5) mL/kg/h. Median (IQR) overall time-average concentration for urea and creatinine were 92 (60) mg/dL and 3.7 (1.7) mg/dL, respectively. The normalized weekly median (IQR) standardized Kt/V was 2.41 (2.29). Eleven dogs (3%) survived to discharge/3-months after treatment. Areas under the ROCC for the APPLE<sub>Full</sub>/APPLE<sub>Fast</sub> scores before CRRT initiation were 0.99 (95% CI, 0.99–1.00) and 0.91 (95% CI, 0.81–1.00), respectively. Optimal cutoff points were < 35 for the APPLE<sub>Full</sub> and < 23 for the APPLE<sub>Fast</sub>, yielding sensitivities/specificities of 100% (95% CI, 74.12%–100.0%)/94.7% (95% CI, 75.36%–99.73%) and 90.9% (95% CI, 62.26%–99.53%)/78.95% (95% CI, 56.67%–91.49%), respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The APPLE scores, unlike clinicopathological findings or the Segev score, proved to be a highly discriminatory prognostic tool. Additionally, the human-derived, KDIGO guideline-based CRRT protocol proved safe and efficacious in dogs undergoing CRRT.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 4","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.70183","citationCount":"0","resultStr":"{\"title\":\"Continuous Renal Replacement Therapy: Application of Kidney Disease Improving Global Outcomes Guidelines for Treatment Prescription in Dogs With Acute Kidney Injury and Outcome Prediction\",\"authors\":\"Hilli Raskansky, Yaron Bruchim, Ran Nivy\",\"doi\":\"10.1111/jvim.70183\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Continuous renal replacement therapy (CRRT) is routinely used in human patients with acute kidney injury (AKI) but studies in dogs are scarce.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To describe CRRT in dogs and assess the utility of a previously validated scoring system for dogs with AKI undergoing hemodialysis, and the Acute Patient Physiological and Laboratory Evaluation (APPLE<sub>Full</sub>/APPLE<sub>Fast</sub>) scores, for outcome prediction.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Animals</h3>\\n \\n <p>Thirty, client-owned dogs.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Cases were retrospectively reviewed. Prognostic scores were calculated upon admission and before CRRT initiation. The CRRT effluent dose followed the KDIGO guidelines. Receiver operating characteristic curves (ROCC) were constructed to evaluate the prognostic utility of these scores.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Median (IQR) serum creatinine (mg/dL) at CRRT initiation, at discharge, and 3 months after discharge were 9.4 (7.4), 3.4 (1), and 1.3 (0.3) respectively. Median (IQR) treatment duration and total number of treatments were 24 (18.5) h and 2 (2) treatments, respectively. The prescribed median (IQR) CRRT effluent dose was 29 (18.5) mL/kg/h. Median (IQR) overall time-average concentration for urea and creatinine were 92 (60) mg/dL and 3.7 (1.7) mg/dL, respectively. The normalized weekly median (IQR) standardized Kt/V was 2.41 (2.29). Eleven dogs (3%) survived to discharge/3-months after treatment. Areas under the ROCC for the APPLE<sub>Full</sub>/APPLE<sub>Fast</sub> scores before CRRT initiation were 0.99 (95% CI, 0.99–1.00) and 0.91 (95% CI, 0.81–1.00), respectively. Optimal cutoff points were < 35 for the APPLE<sub>Full</sub> and < 23 for the APPLE<sub>Fast</sub>, yielding sensitivities/specificities of 100% (95% CI, 74.12%–100.0%)/94.7% (95% CI, 75.36%–99.73%) and 90.9% (95% CI, 62.26%–99.53%)/78.95% (95% CI, 56.67%–91.49%), respectively.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The APPLE scores, unlike clinicopathological findings or the Segev score, proved to be a highly discriminatory prognostic tool. Additionally, the human-derived, KDIGO guideline-based CRRT protocol proved safe and efficacious in dogs undergoing CRRT.</p>\\n </section>\\n </div>\",\"PeriodicalId\":49958,\"journal\":{\"name\":\"Journal of Veterinary Internal Medicine\",\"volume\":\"39 4\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.70183\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Veterinary Internal Medicine\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvim.70183\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.70183","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
Continuous Renal Replacement Therapy: Application of Kidney Disease Improving Global Outcomes Guidelines for Treatment Prescription in Dogs With Acute Kidney Injury and Outcome Prediction
Background
Continuous renal replacement therapy (CRRT) is routinely used in human patients with acute kidney injury (AKI) but studies in dogs are scarce.
Objective
To describe CRRT in dogs and assess the utility of a previously validated scoring system for dogs with AKI undergoing hemodialysis, and the Acute Patient Physiological and Laboratory Evaluation (APPLEFull/APPLEFast) scores, for outcome prediction.
Animals
Thirty, client-owned dogs.
Methods
Cases were retrospectively reviewed. Prognostic scores were calculated upon admission and before CRRT initiation. The CRRT effluent dose followed the KDIGO guidelines. Receiver operating characteristic curves (ROCC) were constructed to evaluate the prognostic utility of these scores.
Results
Median (IQR) serum creatinine (mg/dL) at CRRT initiation, at discharge, and 3 months after discharge were 9.4 (7.4), 3.4 (1), and 1.3 (0.3) respectively. Median (IQR) treatment duration and total number of treatments were 24 (18.5) h and 2 (2) treatments, respectively. The prescribed median (IQR) CRRT effluent dose was 29 (18.5) mL/kg/h. Median (IQR) overall time-average concentration for urea and creatinine were 92 (60) mg/dL and 3.7 (1.7) mg/dL, respectively. The normalized weekly median (IQR) standardized Kt/V was 2.41 (2.29). Eleven dogs (3%) survived to discharge/3-months after treatment. Areas under the ROCC for the APPLEFull/APPLEFast scores before CRRT initiation were 0.99 (95% CI, 0.99–1.00) and 0.91 (95% CI, 0.81–1.00), respectively. Optimal cutoff points were < 35 for the APPLEFull and < 23 for the APPLEFast, yielding sensitivities/specificities of 100% (95% CI, 74.12%–100.0%)/94.7% (95% CI, 75.36%–99.73%) and 90.9% (95% CI, 62.26%–99.53%)/78.95% (95% CI, 56.67%–91.49%), respectively.
Conclusion
The APPLE scores, unlike clinicopathological findings or the Segev score, proved to be a highly discriminatory prognostic tool. Additionally, the human-derived, KDIGO guideline-based CRRT protocol proved safe and efficacious in dogs undergoing CRRT.
期刊介绍：
The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
